M&A Corner
Experity Acquires Teleradiology PACS Platform OnePACS22 Aug 2023
Experity, a major technology partner for U.S. urgent cares, has acquired OnePACS, a medical imaging SaaS company specializing in Picture... Continue Reading
|
Doccla Acquires OpenTeleHealth, Expanding in 12 Markets22 Aug 2023
London-based virtual ward technology provider, Doccla, has acquired cloud-based platform OpenTeleHealth (OTH), expanding its global presence and solidifying its position... Continue Reading
|
Bruker Corporation and PhenomeX Inc. Announce a Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction.22 Aug 2023
Scientific instruments provider Bruker Corporation is set to acquire functional cell biology company PhenomeX for $1.00 per share in an... Continue Reading
|
MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares22 Aug 2023
MediPacific Sub, Inc., affiliated with Foresite Capital, aims to acquire Pardes Biosciences, Inc. at a price of at least $2.02... Continue Reading
|
Orbita Acquires Wellbe Assets, Creating Seamless Digital Pathway22 Aug 2023
Orbita has acquired Wellbe, a digital health company specializing in patient navigation for specialty care. The deal encompasses Wellbe’s software,... Continue Reading
|
Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.22 Aug 2023
Frontage Laboratories, Inc. and its subsidiary Frontage Canada, Inc. have completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics... Continue Reading
|
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals22 Aug 2023
Eyenovia, Inc. has secured exclusive U.S. rights from Formosa Pharmaceuticals to distribute and sell APP13007, a clobetasol propionate ophthalmic nanosuspension... Continue Reading
|
Sanofi Bid First, But Biogen Won Out in Fight to Acquire Reata22 Aug 2023
Biogen Inc. has reportedly outbid Sanofi SA in a closely contested battle to acquire Reata Pharmaceuticals for $7.3 billion. The... Continue Reading
|
RVL Pharmaceuticals (NASDAQ: RVLP) Enters Agreements for $5M Registered Direct Offering22 Aug 2023
RVL Pharmaceuticals, a specialty pharmaceutical firm, has entered definitive agreements for a registered direct offering of around $5 million, set... Continue Reading
|
Athersys, Inc. Announces Pricing of $3.5 Million Public Offering22 Aug 2023
Athersys, Inc. (Nasdaq: ATHX) has announced the pricing of a public offering of 10,937,500 common stock shares at $0.32 per... Continue Reading
|